Frequencies for first 10,000 rows of drug8cl1 variable in nhamcsopd2003 dataset : drug class #1 for medication #8 | Freq. Percent Cum. ----------------------------------------+----------------------------------- anesthetics, local (injectable) | 5 0.05 0.05 anesthetics, general | 11 0.11 0.16 adjuncts to anesthesia/analeptics | 6 0.06 0.22 antidotes, general | 1 0.01 0.23 cephalosporins | 4 0.04 0.27 erythromycins/lincosamides/macrolides | 2 0.02 0.29 sulfonamides and trimethoprim | 2 0.02 0.31 urinary tract antiseptics | 1 0.01 0.32 quinolones/derivatives | 3 0.03 0.35 antiviral agents | 3 0.03 0.38 deficiency anemias | 7 0.07 0.45 anticoagulants/thrombolytics | 10 0.10 0.55 hemostatics/antihemophelics | 1 0.01 0.56 cardiac glycosides | 1 0.01 0.57 antiarrhythmic agents | 3 0.03 0.60 antianginal agents | 9 0.09 0.69 vascular disorders, cerebral/peripheral | 1 0.01 0.70 agents used to treat shock/hypotension | 3 0.03 0.73 antihypertensive agents | 22 0.22 0.95 diuretics | 19 0.19 1.14 calcium channel blockers | 4 0.04 1.18 carbonic anhydrase inhibitors | 1 0.01 1.19 beta blockers | 12 0.12 1.31 alpha agonist/alpha blockers | 3 0.03 1.34 ace inhibitors | 15 0.15 1.49 sedatives and hypnotics | 16 0.16 1.65 antianxiety agents | 7 0.07 1.72 antipsychotic/antimanics | 5 0.05 1.77 antidepressants | 22 0.22 1.99 anorexiants/cns stimulants | 1 0.01 2.00 cns, miscellaneous | 1 0.01 2.01 antiemetics | 3 0.03 2.04 disorders, acid/peptic | 23 0.23 2.27 antidiarrheals | 1 0.01 2.28 laxatives | 10 0.10 2.38 miscellaneous gastrointestinals | 4 0.04 2.42 antispasmodics/anticholinergics | 3 0.03 2.45 antacids | 1 0.01 2.46 hyperlipidemia | 23 0.23 2.69 vitamins/minerals | 29 0.29 2.98 repl/regs of electrolytes/water balance | 18 0.18 3.16 calcium metabolism | 4 0.04 3.20 hematopoietic growth factor | 1 0.01 3.21 adrenal corticosteroids | 5 0.05 3.26 estrogens/progestins | 2 0.02 3.28 blood glucose regulators | 32 0.32 3.60 thyroid/antithyroid | 7 0.07 3.67 contraceptives | 1 0.01 3.68 vaccines/antisera | 4 0.04 3.72 immunomodulators | 3 0.03 3.75 immune serums | 1 0.01 3.76 dermatologics, misc. | 2 0.02 3.78 topical steroids | 2 0.02 3.80 topical anti-infectives | 3 0.03 3.83 anorectal products | 1 0.01 3.84 dermatitis/antipruritics | 1 0.01 3.85 extrapyramidal movement disorders | 1 0.01 3.86 myasthenia gravis | 1 0.01 3.87 skeletal muscle hyperactivity | 5 0.05 3.92 anticonvulsants | 7 0.07 3.99 antineoplastics, miscellaneous | 1 0.01 4.00 hormonal/biological response mod. | 1 0.01 4.01 antimetabolites | 3 0.03 4.04 dna damaging drugs | 1 0.01 4.05 glaucoma | 3 0.03 4.08 ocular anti-infective/anti-inflammatory | 3 0.03 4.11 decongestants/antiallergy agents | 1 0.01 4.12 vertigo/motion sickness/vomiting | 6 0.06 4.18 analgesics, narcotic | 23 0.23 4.41 analgesics, non-narcotic | 31 0.31 4.72 antimigraine/other headaches | 3 0.03 4.75 antiarthritics | 9 0.09 4.84 antigout | 1 0.01 4.85 nsaid | 12 0.12 4.97 antiprotozoals | 1 0.01 4.98 antiasthmatics/bronchodilators | 15 0.15 5.13 nasal decongestants | 2 0.02 5.15 antitussives/expectorants/mucolytics | 1 0.01 5.16 antihistamines | 5 0.05 5.21 corticosteroid-inhalation/nasal | 2 0.02 5.23 miscellaneous/unclassified | 1 0.01 5.24 unclassified | 14 0.14 5.38 homeopathic products | 2 0.02 5.40 . | 9,460 94.60 100.00 ----------------------------------------+----------------------------------- Total | 10,000 100.00 by Jean Roth , jroth@nber.org , 28 Mar 2016